Main Menu


Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have shown that the prostate cancer drug enzalutamide can improve overall survival of men regardless of the severity of their disease.

Prostate Cancer Cells, Prof Johann de Bono for the ICR

Image: Mateus Crespo/Professor Johann de Bono, the ICR

Professor Johann de Bono was the Chief Investigator of the first phase III trial that led to this drug's approval, the AFFIRM trial, which found that enzalutamide significantly prolongs survival of men with advanced prostate cancer when used after docetaxel chemotherapy.

Subsequent studies have shown that enzalutamide also imparts major benefit when given before chemotherapy and improved overall survival, radiographic progression-free survival and time to prostate-specific antigen (PSA) progression compared with placebo across all subgroups.